60 patents
Utility
Ras Inhibitors
23 Nov 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
Filed: 6 Feb 23
Utility
Bicyclic Heteroaryl Compounds and Uses Thereof
16 Nov 23
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
Filed: 11 Oct 22
Utility
Ras Inhibitors
28 Sep 23
The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Andreas Buckl, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Christopher Semko
Filed: 7 Oct 22
Utility
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
27 Jul 23
The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors.
Mallika SINGH, Jingjing JIANG, Yu Chi YANG, James W. EVANS, Christopher J. SCHULZE
Filed: 21 Jun 21
Utility
Ras Inhibitors
27 Jul 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James Cregg, Adrian L. Gill, James Aggen, G. Leslie Burnett, Jennifer Pitzen, Andreas Buckl, John E. Knox, Yang Liu
Filed: 30 Jan 23
Utility
Ras Inhibitors
20 Jul 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Naing AAY, G. Leslie BURNETT, James CREGG, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Yang LIU, Andreas BUCKL, Bianca Jennifer LEE, David E. WILDES, Meghan A. RICE, Mallika SINGH
Filed: 23 Mar 23
Utility
Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
18 Jul 23
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease.
Jie Jack Li, Elena S. Koltun, Adrian Liam Gill, Andreas Buckl, Walter Won, Naing Aay, Kevin Mellem, Christos Tzitzilonis, Ashutosh Jogalekar, James Joseph Cregg
Filed: 10 Apr 20
Utility
Ras inhibitors
4 Jul 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Naing Aay, G. Leslie Burnett, James Cregg, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Andreas Buckl, Bianca Jennifer Lee, David E. Wildes, Meghan A. Rice, Mallika Singh
Filed: 15 Sep 21
Utility
C26-linked rapamycin analogs as mTOR inhibitors
27 Jun 23
The present disclosure relates to mTOR inhibitors.
Christopher Michael Semko, Gang Wang, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Micah James Evans Gliedt, Jennifer Pitzen, Julie Chu-Li Lee, Walter Won, Arun P. Thottumkara, Adrian Liam Gill
Filed: 30 Oct 20
Utility
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
30 May 23
The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
Elena S. Koltun, Kevin Mellem, Adrian Gill, Gert Kiss, Christopher Semko, Naing Aay, Andreas Buckl, Ashutosh Jogalekar, Walter Won
Filed: 18 Jun 20
Utility
CorrectedBicyclic Heteroaryl Compounds and Uses Thereof
11 May 23
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
Andreas BUCKL, James Joseph CREGG, Naing AAY, Arlyn A. TAMBO-ONG, Elena S. KOLTUN, Adrian Liam GILL, Severin THOMPSON, Micah J Gliedt
Filed: 2 Mar 20
Utility
Identifying new therapeutic agents
9 May 23
Disclosed herein are methods for identifying novel drug candidates.
Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
Filed: 21 Dec 20
Utility
Polycyclic compounds as allosteric SHP2 inhibitors
25 Apr 23
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease.
Elena S. Koltun, Naing N. Aay, Andreas Buckl, Kevin T. Mellem, Brian R. Blank, Jennifer Pitzen, Gang Wang, Ashutosh S. Jogalekar, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Adrian Liam Gill, James Joseph Cregg
Filed: 11 Jun 20
Utility
Ras Inhibitors
6 Apr 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
Filed: 5 May 22
Utility
Rapamycin Analogs As Mtor Inhibitors
30 Mar 23
The present disclosure relates to mTOR inhibitors.
James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
Filed: 11 Mar 22
Utility
Bicyclic Heterocyclyl Compounds and Uses Thereof
30 Mar 23
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
James Joseph CREGG, Andreas BUCKL, Naing AAY, Arlyn A. TAMBO-ONG, Elena S. KOLTUN, Adrian Liam GILL, Severin THOMPSON, Micah J. Gliedt
Filed: 2 Mar 20
Utility
Covalent Ras Inhibitors and Uses Thereof
30 Mar 23
The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
Jennifer PITZEN, James AGGEN, G. Leslie BURNETT, Adrian L. GILL, Christopher SEMKO, Anne V. EDWARDS, Micah James GLIEDT, Gert KISS, Ashutosh JOGALEKAR, John E. KNOX, Andreas BUCKL, Elena S. KOLTUN
Filed: 26 May 22
Utility
Ras inhibitors
21 Mar 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. Koltun, James Cregg, Adrian L. Gill
Filed: 4 Nov 20
Utility
SHP2 Inhibitor Dosing and Methods of Treating Cancer
9 Mar 23
Disclosed are SHP2 inhibitor compositions and methods of treating diseases or disorders using an intermittent dosing schedule.
Steve Kelsey, Mallika Singh, Xiaolin Wang, Zhengping Wang
Filed: 30 Jun 22
Utility
SHP2 inhibitor compositions and methods for treating cancer
7 Mar 23
The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.
Robert J. Nichols, Mark A. Goldsmith, Christopher Schulze, Jacqueline Smith, David E. Wildes, Stephen Kelsey, Mallika Singh
Filed: 5 Mar 20